Search research articles
Contact Us
Filters
Showing results (21-30 of 438) with videos related to
Page
of 44
Sort By:
Science Bulletin
|
January 21, 2025
SLC7A11 transporter maintains critical nonessential amino acids levels to hamper ferroptosis during MASLD progression
Elia Casirati, Luca Valenti
Lancet (London, England)
|
February 8, 2026
Once-monthly efimosfermin for non-cirrhotic MASH
Luca Valenti, Giulia Periti
Journal of Hepatology
|
May 31, 2025
Bringing genetic testing into the clinical management of people with MASLD: Are we there yet?
Luca Valenti, Hannes Hagström
PPAR Research
|
February 23, 2013
Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic Fatty liver disease: any role in disease susceptibility?
Paola Dongiovanni, Luca Valenti
Journal of Hepatology
|
March 8, 2020
Update on NAFLD genetics: From new variants to the clinic
Eric Trépo, Luca Valenti
Hepatology (Baltimore, Md.)
|
July 12, 2016
Regulation of retinol-binding protein 4 and retinol metabolism in fatty liver disease
Stefano Romeo, Luca Valenti
Bioinformatics (Oxford, England)
|
October 17, 2017
myVCF: a desktop application for high-throughput mutations data management
Alessandro Pietrelli, Luca Valenti
Hepatobiliary Surgery and Nutrition
|
January 18, 2019
NGM282: a step forward in the nonalcoholic steatohepatitis treatment landscape?
Luca Valenti, Valerio Nobili
International Journal of Molecular Sciences
|
July 18, 2017
A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease
Paola Dongiovanni, Luca Valenti
Journal of Lipid Research
|
November 14, 2018
Beyond fat accumulation, NAFLD genetics converges on lipid droplet biology
Guido Baselli, Luca Valenti
Page
of 44
Search research articles
Search
Showing results (21-30 of 438) with videos related to
Sort By:
Page
of 44
Science Bulletin
|
January 21, 2025
SLC7A11 transporter maintains critical nonessential amino acids levels to hamper ferroptosis during MASLD progression
Elia Casirati, Luca Valenti
Lancet (London, England)
|
February 8, 2026
Once-monthly efimosfermin for non-cirrhotic MASH
Luca Valenti, Giulia Periti
Journal of Hepatology
|
May 31, 2025
Bringing genetic testing into the clinical management of people with MASLD: Are we there yet?
Luca Valenti, Hannes Hagström
PPAR Research
|
February 23, 2013
Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic Fatty liver disease: any role in disease susceptibility?
Paola Dongiovanni, Luca Valenti
Journal of Hepatology
|
March 8, 2020
Update on NAFLD genetics: From new variants to the clinic
Eric Trépo, Luca Valenti
Hepatology (Baltimore, Md.)
|
July 12, 2016
Regulation of retinol-binding protein 4 and retinol metabolism in fatty liver disease
Stefano Romeo, Luca Valenti
Bioinformatics (Oxford, England)
|
October 17, 2017
myVCF: a desktop application for high-throughput mutations data management
Alessandro Pietrelli, Luca Valenti
Hepatobiliary Surgery and Nutrition
|
January 18, 2019
NGM282: a step forward in the nonalcoholic steatohepatitis treatment landscape?
Luca Valenti, Valerio Nobili
International Journal of Molecular Sciences
|
July 18, 2017
A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease
Paola Dongiovanni, Luca Valenti
Journal of Lipid Research
|
November 14, 2018
Beyond fat accumulation, NAFLD genetics converges on lipid droplet biology
Guido Baselli, Luca Valenti
Page
of 44